- Email: [email protected]
Corrigendum to “Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats” [Eur. J. Pharmacol. 423 (2001) 27–33]
European Journal of Pharmacology 428 Ž2001. 389–390 www.elsevier.comrlocaterejphar
Corrigendum to ANeuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in ratsB wEur. J. Pharmacol. 423 ž2001/ 27–33x q Naoya Kawashima) , Takeo Funakoshi, Tomohiro Omura, Shigeyuki Chaki, Kazuya Kameo, Shigeru Okuyama CNS Diseases Research, Medicinal Pharmacology Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama 330-8530, Japan
The authors regret that in the above-mentioned article errors were made. The following points need to be considered: Figs. 3 and 4 should change place with each other. Fig. 3 should show
q )
recording data of electrophysiology and Fig. 4 should show graphs. The legends are correct. The correct figures plus legends are given on the following page.
PII of original article S0014-2999Ž01.01085-8 Corresponding author. E-mail address: [email protected] ŽN. Kawashima..
0014-2999r01r$ - see front matter q 2001 Elsevier Science B.V. All rights reserved. PII: S 0 0 1 4 - 2 9 9 9 Ž 0 1 . 0 1 2 9 2 - 4
390
N. Kawashima et al.r European Journal of Pharmacology 428 (2001) 389–390
Fig. 3. Reversal by NRA0562 of the inhibitory effects of methamphetamine Ž1 mgrkg, i.v.. on A10 ŽA. and A9 ŽB. dopamine neurons.
Fig. 4. Comparison of the potential of NRA0562 ŽA. and risperidone ŽB. to reverse the inhibitory effects of methamphetamine Ž1 mgrkg, i.v.. on A10 Ž. and A9 Ž. dopamine neurons. The results are presented as means with vertical lines showing S.E. Ž ns6.. Starting doses of NRA0562 and risperidone were 0.1 and 0.01 mgrkg, i.v., respectively. ) ) P - 0.01 vs. pre-drug value ŽDunnett’s test.. aaP - 0.01 vs. methamphetamineq vehicle-treated group ŽDunnett’s test..
Corrigendum to ANeuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in ratsB wEur. J. Pharmacol. 423 ž2001/ 27–33x q Naoya Kawashima) , Takeo Funakoshi, Tomohiro Omura, Shigeyuki Chaki, Kazuya Kameo, Shigeru Okuyama CNS Diseases Research, Medicinal Pharmacology Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama 330-8530, Japan
The authors regret that in the above-mentioned article errors were made. The following points need to be considered: Figs. 3 and 4 should change place with each other. Fig. 3 should show
q )
recording data of electrophysiology and Fig. 4 should show graphs. The legends are correct. The correct figures plus legends are given on the following page.
PII of original article S0014-2999Ž01.01085-8 Corresponding author. E-mail address: [email protected] ŽN. Kawashima..
0014-2999r01r$ - see front matter q 2001 Elsevier Science B.V. All rights reserved. PII: S 0 0 1 4 - 2 9 9 9 Ž 0 1 . 0 1 2 9 2 - 4
390
N. Kawashima et al.r European Journal of Pharmacology 428 (2001) 389–390
Fig. 3. Reversal by NRA0562 of the inhibitory effects of methamphetamine Ž1 mgrkg, i.v.. on A10 ŽA. and A9 ŽB. dopamine neurons.
Fig. 4. Comparison of the potential of NRA0562 ŽA. and risperidone ŽB. to reverse the inhibitory effects of methamphetamine Ž1 mgrkg, i.v.. on A10 Ž. and A9 Ž. dopamine neurons. The results are presented as means with vertical lines showing S.E. Ž ns6.. Starting doses of NRA0562 and risperidone were 0.1 and 0.01 mgrkg, i.v., respectively. ) ) P - 0.01 vs. pre-drug value ŽDunnett’s test.. aaP - 0.01 vs. methamphetamineq vehicle-treated group ŽDunnett’s test..